Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Launches $100M Share Repurchase Program

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina announced today that its board of directors has authorized a $100 million share repurchase program.

The firm may acquire on a discretionary basis up to $100 million worth of its outstanding common shares on the open market or through privately negotiated transactions. Its previous $100 million share repurchase program, which was authorized in July 2010, was completed this week, the firm said.

"We believe that the repurchase of our common stock represents an effective use of our capital and underscores our commitment to maximize value for our shareholders, " Illumina CFO and GM of Life Sciences Christian Henry said in a statement. "Since 2008, we have bought over 12 million shares of our common stock through prior authorizations, returning nearly $450 million to shareholders."

Last week, Illumina reported a 36 percent increase in its second quarter sales year over year. It finished the quarter with $261.1 million in cash and cash equivalents and $972.8 million in short-term investments.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.